Personalis

Personalis, Inc. is a biotechnology company that develops genomic sequencing technologies and data analytics for clinical diagnostics and life-science research. The company concentrates on next-generation sequencing (NGS) workflows and bioinformatics to support oncology, transplant medicine, and infectious disease applications. Its offerings are designed for use by clinical laboratories, research institutions, and pharmaceutical partners seeking high-resolution genomic data and interpretable results.

Its portfolio typically includes sequencing services, library preparation technologies, and an integrated software platform that processes raw sequencing data into actionable biomarkers. Common capabilities include detection of somatic mutations and structural variants in tumors, analysis of copy number alterations, and profiling of immune repertoires. In transplantation contexts, genomic analysis supports donor-recipient matching and post-transplant monitoring. In infectious disease areas, sequencing-based surveillance and pathogen characterization are among potential applications.

Historically, Personalis has engaged in collaborations with academic centers, biopharmaceutical companies, and clinical laboratories to develop and validate NGS-based diagnostics and companion tests. The company operates in the United States and internationally, serving customers across research, clinical, and pharmaceutical ecosystems.